WINNIPEG, MANITOBA--(MARKET WIRE)--Jul 27, 2007 -- Medicure Inc. (Toronto:MPH.TO - News)(AMEX:MCU - News), a cardiovascular focused, biopharmaceutical company, today announced that data from MR PCI (Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition), a head-to-head study comparing the platelet inhibition effects of AGGRASTAT® (tirofiban hydrochloride) and INTEGRILIN® (eptifibatide), will be published in the August edition of the American Heart Journal.
